IL127708A - Matrix for administering drugs through the skin to administer estradiol and another steroid at the same time - Google Patents
Matrix for administering drugs through the skin to administer estradiol and another steroid at the same timeInfo
- Publication number
- IL127708A IL127708A IL12770897A IL12770897A IL127708A IL 127708 A IL127708 A IL 127708A IL 12770897 A IL12770897 A IL 12770897A IL 12770897 A IL12770897 A IL 12770897A IL 127708 A IL127708 A IL 127708A
- Authority
- IL
- Israel
- Prior art keywords
- estradiol
- concentration
- steroid
- matrix layer
- transdermal patch
- Prior art date
Links
- 239000011159 matrix material Substances 0.000 title claims abstract description 73
- 150000003431 steroids Chemical class 0.000 title claims abstract description 52
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 title claims abstract description 42
- 229960005309 estradiol Drugs 0.000 title claims abstract description 41
- 229930182833 estradiol Natural products 0.000 title claims abstract description 41
- 238000013271 transdermal drug delivery Methods 0.000 title description 4
- 230000004907 flux Effects 0.000 claims abstract description 90
- 229920001577 copolymer Polymers 0.000 claims abstract description 19
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims abstract description 8
- 150000002148 esters Chemical class 0.000 claims abstract description 5
- 239000003163 gonadal steroid hormone Substances 0.000 claims abstract 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 80
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 53
- 229960001652 norethindrone acetate Drugs 0.000 claims description 53
- 229960003604 testosterone Drugs 0.000 claims description 40
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 28
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 8
- 239000001593 sorbitan monooleate Substances 0.000 claims description 8
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 8
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 8
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 6
- 229960004400 levonorgestrel Drugs 0.000 claims description 6
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims description 4
- 229960005352 gestodene Drugs 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000003961 penetration enhancing agent Substances 0.000 claims description 4
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 claims description 3
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 claims description 3
- 229960004976 desogestrel Drugs 0.000 claims description 3
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims description 3
- 229960001566 methyltestosterone Drugs 0.000 claims description 3
- 229940053934 norethindrone Drugs 0.000 claims description 3
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 3
- 229960003387 progesterone Drugs 0.000 claims description 3
- 239000000186 progesterone Substances 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 claims description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims description 2
- 238000002657 hormone replacement therapy Methods 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 2
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 claims 5
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- CGELCEJMFKCGRN-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;2-ethylhexyl prop-2-enoate Chemical compound C=CN1CCCC1=O.CCCCC(CC)COC(=O)C=C CGELCEJMFKCGRN-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 127
- 238000009472 formulation Methods 0.000 description 98
- 210000003491 skin Anatomy 0.000 description 63
- 230000001070 adhesive effect Effects 0.000 description 44
- 239000000853 adhesive Substances 0.000 description 43
- 238000000338 in vitro Methods 0.000 description 34
- 239000003814 drug Substances 0.000 description 29
- 229940079593 drug Drugs 0.000 description 28
- 238000011068 loading method Methods 0.000 description 28
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 27
- 238000012360 testing method Methods 0.000 description 21
- 229920006243 acrylic copolymer Polymers 0.000 description 19
- 230000001186 cumulative effect Effects 0.000 description 10
- 238000005266 casting Methods 0.000 description 9
- 229960004592 isopropanol Drugs 0.000 description 9
- 238000012417 linear regression Methods 0.000 description 8
- 239000000654 additive Substances 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 241000769223 Thenea Species 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- FDVCQFAKOKLXGE-UHFFFAOYSA-N 216978-79-9 Chemical compound C1CC(C)(C)C2=CC(C=O)=CC3=C2N1CCC3(C)C FDVCQFAKOKLXGE-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WDPFQABQVGJEBZ-MAKOZQESSA-N Bothermon Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 WDPFQABQVGJEBZ-MAKOZQESSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical class CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002159 estradiols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 229940116335 lauramide Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102220032891 rs367543178 Human genes 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/683,892 US5783208A (en) | 1996-07-19 | 1996-07-19 | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
| PCT/US1997/011673 WO1998003137A1 (en) | 1996-07-19 | 1997-07-02 | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL127708A0 IL127708A0 (en) | 1999-10-28 |
| IL127708A true IL127708A (en) | 2004-02-19 |
Family
ID=24745888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12770897A IL127708A (en) | 1996-07-19 | 1997-07-02 | Matrix for administering drugs through the skin to administer estradiol and another steroid at the same time |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5783208A (de) |
| EP (1) | EP0921774B1 (de) |
| JP (2) | JP4212115B2 (de) |
| KR (1) | KR100628796B1 (de) |
| CN (2) | CN1204859C (de) |
| AT (1) | ATE339172T1 (de) |
| AU (1) | AU714590B2 (de) |
| BR (1) | BR9710738A (de) |
| CA (1) | CA2259532C (de) |
| DE (1) | DE69736671T2 (de) |
| DK (1) | DK0921774T3 (de) |
| ES (1) | ES2271970T3 (de) |
| HK (2) | HK1020864A1 (de) |
| HU (1) | HUP9904369A3 (de) |
| IL (1) | IL127708A (de) |
| NO (1) | NO325232B1 (de) |
| NZ (1) | NZ333558A (de) |
| PL (1) | PL188009B1 (de) |
| PT (1) | PT921774E (de) |
| WO (1) | WO1998003137A1 (de) |
| ZA (1) | ZA976035B (de) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252334A (en) * | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
| US6407082B1 (en) * | 1996-09-13 | 2002-06-18 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a vitamin D compound |
| US20020048596A1 (en) * | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
| IL122432A (en) * | 1995-06-07 | 2000-07-16 | Cygnus Therapeutic Systems | Transdermal patch for preventing ovulation |
| US6511970B1 (en) | 1996-09-13 | 2003-01-28 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
| US6034074A (en) | 1996-09-13 | 2000-03-07 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a Vitamin D compound |
| US6028064A (en) | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
| US6765002B2 (en) | 2000-03-21 | 2004-07-20 | Gustavo Rodriguez | Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium |
| US6624200B2 (en) | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US6248358B1 (en) | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
| US8765177B2 (en) * | 1997-09-12 | 2014-07-01 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US7153845B2 (en) * | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| DE19834007C1 (de) * | 1998-07-29 | 2000-02-24 | Lohmann Therapie Syst Lts | Estradiolhaltiges Pflaster zur transdermalen Applikation von Hormonen und seine Verwendung |
| JP4838936B2 (ja) * | 1998-10-23 | 2011-12-14 | イデア アクチェンゲゼルシャフト | 装荷量を改善しおよび脱／会合速度を制御可能とするための、巨大分子と複合凝集体との会合体を開発し、テストし、かつ利用する方法 |
| US6984404B1 (en) | 1998-11-18 | 2006-01-10 | University Of Florida Research Foundation, Inc. | Methods for preparing coated drug particles and pharmaceutical formulations thereof |
| AU2051600A (en) * | 1998-12-10 | 2000-06-26 | Board Of Regents, The University Of Texas System | Compositions and methods of modulating cholesterol metabolism |
| ES2173678T3 (es) | 1999-01-27 | 2002-10-16 | Idea Ag | Vacunacion no invasiva a traves de la piel. |
| SI1031347T1 (en) | 1999-01-27 | 2002-10-31 | Idea Ag | Transnasal transport/immunisation with highly adaptable carriers |
| US6297337B1 (en) | 1999-05-19 | 2001-10-02 | Pmd Holdings Corp. | Bioadhesive polymer compositions |
| EP1754488A1 (de) | 1999-05-24 | 2007-02-21 | Introgen Therapeutics, Inc. | Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten |
| US6406745B1 (en) | 1999-06-07 | 2002-06-18 | Nanosphere, Inc. | Methods for coating particles and particles produced thereby |
| AU5409699A (en) * | 1999-07-05 | 2001-01-22 | Idea Ag | A method for the improvement of transport across adaptable semi-permeable barriers |
| US20010044431A1 (en) * | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| US7029694B2 (en) | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| CA2406064C (en) | 2000-04-26 | 2011-03-15 | Watson Pharmaceuticals, Inc. | Minimizing adverse experience associated with oxybutynin therapy |
| US7179483B2 (en) * | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| US20030124177A1 (en) * | 2000-04-26 | 2003-07-03 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| US10293056B1 (en) | 2000-05-24 | 2019-05-21 | Board Of Regents, The University Of Texas System | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| JP4271028B2 (ja) * | 2001-08-10 | 2009-06-03 | 久光製薬株式会社 | 経皮吸収型製剤 |
| KR20030041596A (ko) * | 2001-11-20 | 2003-05-27 | 삼일페인트공업 주식회사 | 의료용 팻치에 적용되는 아크릴 점착제의 제조방법 |
| US7921999B1 (en) | 2001-12-20 | 2011-04-12 | Watson Laboratories, Inc. | Peelable pouch for transdermal patch and method for packaging |
| US7473432B2 (en) * | 2002-10-11 | 2009-01-06 | Idea Ag | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
| GB0409498D0 (en) * | 2004-04-28 | 2004-06-02 | Hunter Fleming Ltd | Transdermal steroid formulation |
| EP1811961A2 (de) * | 2004-11-12 | 2007-08-01 | Idea Ag | Erweiterte oberflächen-aggregate bei der behandlung von hauterkrankungen |
| US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| US10137135B2 (en) * | 2005-08-15 | 2018-11-27 | Allergan Sales, Llc | Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith |
| GEP20125432B (en) | 2005-10-12 | 2012-03-26 | Unimed Pharmaceuticals Llc | Improved testosterone gel and use thereof |
| US20090169602A1 (en) * | 2005-11-23 | 2009-07-02 | Universität Zürich | Allergy Treatment by Epicutaneous Allergen Administration |
| CN101370453B (zh) * | 2005-12-14 | 2013-12-18 | 努沃研究公司 | 用于皮肤输送药物的组合物和方法 |
| WO2007092944A2 (en) * | 2006-02-08 | 2007-08-16 | Introgen Therapeutics, Inc. | Compositions and methods involving gene therapy and proteasome modulation |
| US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
| US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
| US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
| CA2667678A1 (en) | 2006-10-25 | 2008-07-24 | Amgen Inc. | Toxin peptide therapeutic agents |
| WO2008106646A2 (en) * | 2007-03-01 | 2008-09-04 | Introgen Therapeutics, Inc | Methods and formulations for topical gene therapy |
| EP3492596A1 (de) | 2007-04-09 | 2019-06-05 | University of Florida Research Foundation, Inc. | Raav-vektorzusammensetzungen mit tyrosinmodifizierten kapsidproteinen und verfahren zu deren verwendung |
| CA2687141C (en) | 2007-05-22 | 2014-04-01 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
| US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| EP2772267B1 (de) | 2007-08-27 | 2016-04-27 | Longhorn Vaccines and Diagnostics, LLC | Immunogene Zusammensetzungen und Verfahren |
| US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
| DK2535428T3 (en) | 2007-10-01 | 2015-11-23 | Longhorn Vaccines & Diagnostics Llc | Biological prøvesamlings- and transport system, and methods of using |
| WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| EP2561067B1 (de) | 2010-04-23 | 2018-11-14 | University of Florida Research Foundation, Inc. | Raav-guanylat-cyclase-zusammensetzungen und verfahren zur behandlung der leberschen kongenitalen amaurose-1 (lca1) |
| EP2826860B1 (de) | 2010-04-23 | 2018-08-22 | University of Massachusetts | Auf das ZNS abzielende AAV Vektoren und Verfahren zur Verwendung davon |
| EP3444346B1 (de) | 2010-04-23 | 2022-07-27 | University of Massachusetts | Aav-basierte behandlung von cholesterinerkrankungen |
| AU2012228990B2 (en) | 2011-03-16 | 2017-04-06 | Amgen Inc. | Potent and selective inhibitors of Nav1.3 and Nav1.7 |
| US9226976B2 (en) | 2011-04-21 | 2016-01-05 | University Of Massachusetts | RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies |
| US10149834B2 (en) | 2011-12-01 | 2018-12-11 | Teikoku Seiyaku Co., Ltd. | Ropinirole-containing adhesive patch |
| EP2786752B1 (de) | 2011-12-01 | 2019-06-12 | Teikoku Seiyaku Co., Ltd. | Ropinirolhaltige heftpflaster |
| CA3207612A1 (en) | 2012-01-26 | 2013-08-01 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| UY35397A (es) | 2013-03-12 | 2014-10-31 | Amgen Inc | INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7 |
| US10280418B2 (en) | 2014-03-18 | 2019-05-07 | Univeristy Of Massachusetts | RAAV-based compositions and methods for treating amyotrophic lateral sclerosis |
| WO2015164786A1 (en) | 2014-04-25 | 2015-10-29 | University Of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
| US10711270B2 (en) | 2014-10-03 | 2020-07-14 | University Of Massachusetts | High efficiency library-identified AAV vectors |
| RU2020140209A (ru) | 2014-10-21 | 2021-01-25 | Юниверсити Оф Массачусетс | Варианты рекомбинантных aav и их применения |
| EP3233131A1 (de) | 2014-12-16 | 2017-10-25 | Board of Regents of the University of Nebraska | Gentherapie für juvenile neuronale ceroid-lipofuszinose |
| WO2016183292A1 (en) | 2015-05-14 | 2016-11-17 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
| CN108601811A (zh) | 2015-12-04 | 2018-09-28 | 得克萨斯州大学系统董事会 | 用于免疫治疗的slc45a2肽 |
| DK3423110T3 (da) | 2016-03-03 | 2021-11-15 | Univ Massachusetts | Lineært duplex-dna med lukket ende til ikke-viral genoverførsel |
| CA3034527A1 (en) | 2016-08-23 | 2018-03-01 | Emmanuel John Simons | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
| US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
| AU2017341849B2 (en) | 2016-10-13 | 2024-03-21 | University Of Massachusetts | AAV capsid designs |
| US11318190B2 (en) | 2017-05-05 | 2022-05-03 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating liver disease |
| KR20200135433A (ko) | 2018-03-23 | 2020-12-02 | 유니버시티 오브 매사추세츠 | 골 장애 치료를 위한 유전자 치료제 |
| EP3784290A4 (de) | 2018-04-27 | 2022-03-23 | University of Massachusetts | Durch in-vivo-bibliotheksauswahl identifizierte aav-kapside |
| US20220033824A1 (en) | 2018-11-29 | 2022-02-03 | University Of Massachusetts | Modulation of sptlc1 via recombinant adeno-associated vectors |
| US20220054655A1 (en) | 2019-02-22 | 2022-02-24 | University Of Massachusetts | Oxr1 gene therapy |
| CN114555814A (zh) | 2019-09-13 | 2022-05-27 | 罗特格斯新泽西州立大学 | Aav相容的层粘连蛋白-连接子聚合蛋白 |
| IL295747A (en) | 2020-02-21 | 2022-10-01 | Akouos Inc | Preparations and methods for the treatment of hearing impairment that is not related to age in humans |
| MX2022012279A (es) | 2020-03-31 | 2023-02-23 | Univ Massachusetts | Variantes de capsides de aav y usos de los mismos. |
| CA3178726A1 (en) | 2020-05-21 | 2021-11-25 | Gregory LIZEE | T cell receptors with vgll1 specificity and uses thereof |
| MX2023001998A (es) | 2020-08-17 | 2023-05-04 | Massachusetts Inst Technology | Enfoques de terapia con el gen shank3. |
| EP4255457A1 (de) | 2020-12-03 | 2023-10-11 | University of Massachusetts | Entwicklung von neuen gentherapeutika für fibrodysplasia ossificans progressiva |
| EP4337197A1 (de) | 2021-05-10 | 2024-03-20 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Pharmazeutische zusammensetzungen zur behandlung neurologischer erkrankungen |
| AU2022356427A1 (en) | 2021-09-30 | 2024-05-09 | Akouos, Inc. | Compositions and methods for treating kcnq4-associated hearing loss |
| WO2023164545A1 (en) | 2022-02-23 | 2023-08-31 | Massachusetts Institute Of Technology | Methods for upregulating shank3 expression |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4954487A (en) * | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
| IL61721A (en) * | 1980-12-16 | 1984-03-30 | Blank Izhak | Nitroglycerin preparations |
| US4537776A (en) * | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
| JPS60123417A (ja) * | 1983-12-07 | 1985-07-02 | Nitto Electric Ind Co Ltd | 薬物投与部材 |
| JPS6160620A (ja) * | 1984-09-03 | 1986-03-28 | Teijin Ltd | ピログルタミン酸エステル類を含有する医薬品組成物 |
| US5296230A (en) * | 1985-02-25 | 1994-03-22 | Rutgers, The State University Of New Jersey | Transdermal fertility control system and process |
| US4762851A (en) * | 1985-11-29 | 1988-08-09 | Merck & Co., Inc. | Pyroglutamic acid esters used as dermal penetration enhancers for drugs |
| US5023084A (en) * | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
| US4994267A (en) * | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Transdermal acrylic multipolymer drug delivery system |
| GB8811408D0 (en) * | 1988-05-13 | 1988-06-15 | Unilever Plc | Cosmetic composition |
| CA2000401C (en) * | 1988-10-11 | 1996-05-28 | Masato Azuma | Percutaneous pharmaceutical preparation |
| US5512292A (en) * | 1990-10-29 | 1996-04-30 | Alza Corporation | Transdermal contraceptive formulations methods and devices |
| JPH04342532A (ja) * | 1991-05-21 | 1992-11-30 | Sekisui Chem Co Ltd | 経皮吸収貼付剤 |
| JP3086288B2 (ja) * | 1991-07-23 | 2000-09-11 | 扶桑薬品工業株式会社 | 経皮吸収製剤 |
| JP2948423B2 (ja) * | 1992-08-19 | 1999-09-13 | 富士写真フイルム株式会社 | カリウムイオン分析用イオン選択電極 |
| US5460820B1 (en) * | 1993-08-03 | 1999-08-03 | Theratech Inc | Method for providing testosterone and optionally estrogen replacement therapy to women |
| AU692504B2 (en) * | 1993-12-27 | 1998-06-11 | Akzo Nobel N.V. | Percutaneously absorbable preparation |
| FR2717688B1 (fr) * | 1994-03-28 | 1996-07-05 | Lhd Lab Hygiene Dietetique | Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA. |
| JPH0827003A (ja) * | 1994-07-22 | 1996-01-30 | Sekisui Chem Co Ltd | 経皮吸収製剤 |
| US5780050A (en) * | 1995-07-20 | 1998-07-14 | Theratech, Inc. | Drug delivery compositions for improved stability of steroids |
| DE19629468A1 (de) * | 1996-07-11 | 1998-01-15 | Schering Ag | Transdermale therapeutische Systeme |
-
1996
- 1996-07-19 US US08/683,892 patent/US5783208A/en not_active Expired - Lifetime
-
1997
- 1997-07-02 DK DK97933279T patent/DK0921774T3/da active
- 1997-07-02 ES ES97933279T patent/ES2271970T3/es not_active Expired - Lifetime
- 1997-07-02 AT AT97933279T patent/ATE339172T1/de not_active IP Right Cessation
- 1997-07-02 BR BR9710738A patent/BR9710738A/pt not_active Application Discontinuation
- 1997-07-02 NZ NZ333558A patent/NZ333558A/xx unknown
- 1997-07-02 PT PT97933279T patent/PT921774E/pt unknown
- 1997-07-02 CN CNB971965633A patent/CN1204859C/zh not_active Expired - Fee Related
- 1997-07-02 AU AU36503/97A patent/AU714590B2/en not_active Ceased
- 1997-07-02 KR KR1019997000406A patent/KR100628796B1/ko not_active IP Right Cessation
- 1997-07-02 WO PCT/US1997/011673 patent/WO1998003137A1/en active IP Right Grant
- 1997-07-02 PL PL33123997A patent/PL188009B1/pl not_active IP Right Cessation
- 1997-07-02 DE DE69736671T patent/DE69736671T2/de not_active Expired - Lifetime
- 1997-07-02 JP JP50695598A patent/JP4212115B2/ja not_active Expired - Lifetime
- 1997-07-02 EP EP97933279A patent/EP0921774B1/de not_active Expired - Lifetime
- 1997-07-02 CN CNB2004100831783A patent/CN100536835C/zh not_active Expired - Fee Related
- 1997-07-02 HU HU9904369A patent/HUP9904369A3/hu unknown
- 1997-07-02 CA CA002259532A patent/CA2259532C/en not_active Expired - Lifetime
- 1997-07-02 IL IL12770897A patent/IL127708A/en not_active IP Right Cessation
- 1997-07-07 ZA ZA9706035A patent/ZA976035B/xx unknown
-
1999
- 1999-01-15 NO NO19990179A patent/NO325232B1/no not_active IP Right Cessation
-
2000
- 2000-01-03 HK HK00100001A patent/HK1020864A1/xx not_active IP Right Cessation
-
2005
- 2005-11-18 HK HK05110412.4A patent/HK1078470A1/xx not_active IP Right Cessation
-
2006
- 2006-09-26 JP JP2006261578A patent/JP2006342186A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5783208A (en) | Transdermal drug delivery matrix for coadministering estradiol and another steroid | |
| US5554381A (en) | Low flux matrix system for delivering potent drugs transdermally | |
| US5164190A (en) | Subsaturated transdermal drug delivery device exhibiting enhanced drug flux | |
| KR100215027B1 (ko) | 스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형 | |
| AU710760B2 (en) | Drug delivery compositions for improved stability of steroids | |
| US5460820A (en) | Methods for providing testosterone and optionally estrogen replacement therapy to women | |
| AU696777B2 (en) | Triacetin as a transdermal penetration enhancer | |
| AU671020B2 (en) | Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration | |
| US6531149B1 (en) | Estradiol-containing patch for transdermal application of hormones | |
| AU681383B2 (en) | Active-substance patch for releasing estradiol to the skin | |
| ZA200403658B (en) | Transdermal therapeutic systems containing steroid hormones and propylene glycol monocaprylate. | |
| CZ300976B6 (cs) | Transdermální náplast, obsahující alespon jednu úcinnou složku ovlivnující hladinu lipidu v krevním séru | |
| JP2003063955A (ja) | 経皮吸収型貼付剤 | |
| MXPA99000683A (en) | Matrix for the transdermal release of a pharmacy, to coordinate estradiol and another estero | |
| KR960013236B1 (ko) | 에스트로겐/프로게스틴 경피 전달 장치 및 이를 포함하는 키트 | |
| KR100400524B1 (ko) | 약물의경피흡수성이뛰어난경피투여제형 | |
| AU2003240942A1 (en) | Norethindrone sustained release formulations and methods associated therewith | |
| CA2338861A1 (en) | Estradiol-containing patch for transdermal administration of hormones | |
| MXPA01001042A (en) | Estradiol-containing patch for transdermal administration of hormones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |